MarketInOut Stock Screener Log In | Sign Up

Can-Fite BioPharma Ltd

TLV • Healthcare • Biotechnology • Quote as of 10/30/2026
Can-Fite BioPharma Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization16.91 mln
Float6.06 mln
Earnings Date11/13/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

2 / 100
Severely lagging

Debt / Equity

0.01
Debt-free

Pre-Tax Margin

-2,362%
Severely loss-making

ROE

-196
Deeply negative

Altman Z-Score

-27.73
Deeply distressed

Business Description

Can-Fite BioPharma is an Israeli drug development company focused on creating oral treatments for cancer, liver disease, and erectile dysfunction. Its most advanced medicines, Piclidenoson and Namodenoson, are being tested in late-stage clinical trials targeting conditions such as psoriasis, liver cancer, and metabolic liver disease. The company also partners with other firms to expand the reach of its treatments and explore cannabis-based therapies for cancer and inflammatory conditions. Founded in 1994 and based in Ramat Gan, Israel, Can-Fite also offers a blood test kit designed to help predict how patients may respond to its drugs.

Key Fundamentals

EPS-21.06
ROE-196
RPS0.33
ROIC-734
ROA-113
EBITDA, mln-30.34
EV / EBITDA0.08
EV / EBIT0.08
Revenue, mln1.28

Quote Details

Last 263.30
Change 0.4 (0.15%)
Open 262.90
Volume 4,670
Turnover 1,229,611
Average Volume 13,704

Financial Ratios

Pre-Tax Profit Margin-2,362
Leverage Ratio1.66
Current Ratio3.60
Price / Book0.98
Price / Tangible Book0.97
Debt / Equity0.01
Price / Sales7.83

Financial Strength

Altman Z-Score-27.73
Piotroski F-Score 2 / 9

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -14.65% 2 / 100   
1 Month -20.24% 4 / 100   
2 Months -45.78% 2 / 100   
6 Months -45.67% 5 / 100   
1 Year -91.22% 0 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog